TABLE 5.
Comparison of clinicopathologic characteristics between high and low PPFA/PA
| Variables | Low PPFA/PA (N = 90) | High PPFA/PA (N = 42) | p Value |
|---|---|---|---|
| Age (years) | 71 (51–84) | 68 (36–85) | 0.833 |
| BMI (kg/m2) | 23.58 (18.51–30.64) | 24.96 (20.76–29.30) | 0.012 |
| ECOG score | |||
| 0 or 1 | 64 (71.11%) | 22 (52.38%) | 0.035 |
| 2 | 26 (28.89%) | 20 (47.62%) | |
| ISUP grading group | |||
| 1 | 9 (10%) | 3 (7.14%) | 0.311 |
| 2 | 19 (21.11%) | 3 (7.14%) | |
| 3 | 27 (30%) | 7 (16.67%) | |
| 4 | 26 (28.89%) | 19 (45.24%) | |
| 5 | 9 (10%) | 10 (23.81%) | |
| Clinical T stage | |||
| 2 | 15 (16.67%) | 6 (14.9%) | 0.001 |
| 3 | 46 (51.11%) | 9 (21.43%) | |
| 4 | 29 (32.22%) | 27 (64.28%) | |
| ADT duration before AA | |||
| <12 months | 38 (42.22%) | 29 (69.05%) | 0.004 |
| ≥12 months | 52 (57.78%) | 13 (30.95%) | |
| Metastatic sites | |||
| Bone only | 49 (54.44%) | 15 (35.71%) | 0.045 |
| Viscera | 41 (45.56%) | 27 (64.29%) | |
| PSA at diagnosis (ng/ml) | 13.10 (4.59–56.64) | 13.05 (4.10–96.00) | 0.792 |
| PSA at abiraterone start (ng/ml) | 9.76 (1.11–91.76) | 12.60 (2.34–77.07) | 0.267 |
| PSA nadir after AA treatment (ng/ml) | 2.96 (0.02–40.00) | 8.97 (1.25–48.12) | <0.001 |
| PSA reduction (%) | 67.47 (−64.83–99.51) | 28.22 (−87.10–90.20) | <0.001 |
| Biochemical progression | |||
| Yes | 61 (67.78%) | 37 (88.10%) | 0.013 |
| No | 29 (32.22%) | 5 (11.90%) | |
| Radiological progression | |||
| Yes | 47 (52.22%) | 35 (83.33%) | 0.001 |
| No | 43 (47.78%) | 7 (16.67%) |
Abbreviations: AA, abiraterone acetate; ADT, androgen deprivation therapy; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group performance status score; ISUP, International Society of Urological Pathology; PPFA/PA, periprostatic fat area/prostate area; PSA, prostate‐specific antigen.